Evidence map›Paper›PMID 39467935›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Serum alpha klotho levels in Parkinson's Disease.

Ahmet Yalcin, Emine Gemci, Busra Yurumez, Rezzak Yilmaz, Murat Varli, Volkan Atmis, M Cenk Akbostancı, Nuray Yazihan

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmet YalcinGeriatric Medicine Department, Ankara University School of Medicine, Ankara Üniversitesi Tıp Fakültesi Dekanlığı Morfoloji Yerleşkesi, A. Adnan Saygun Cad. No: 35, Altındağ/Ankara, Turkey. ahmetemreyalcin@hotmail.com.ORCID http://orcid.org/0000-0001-9472-2212
Emine GemciGeriatric Medicine Department, Ankara University School of Medicine, Ankara Üniversitesi Tıp Fakültesi Dekanlığı Morfoloji Yerleşkesi, A. Adnan Saygun Cad. No: 35, Altındağ/Ankara, Turkey.
Busra YurumezGeriatric Medicine Department, Ankara University School of Medicine, Ankara Üniversitesi Tıp Fakültesi Dekanlığı Morfoloji Yerleşkesi, A. Adnan Saygun Cad. No: 35, Altındağ/Ankara, Turkey.
Rezzak YilmazNeurology Department, Ankara University School of Medicine, Ankara, Turkey.
Murat VarliGeriatric Medicine Department, Ankara University School of Medicine, Ankara Üniversitesi Tıp Fakültesi Dekanlığı Morfoloji Yerleşkesi, A. Adnan Saygun Cad. No: 35, Altındağ/Ankara, Turkey.
Volkan AtmisGeriatric Medicine Department, Ankara University School of Medicine, Ankara Üniversitesi Tıp Fakültesi Dekanlığı Morfoloji Yerleşkesi, A. Adnan Saygun Cad. No: 35, Altındağ/Ankara, Turkey.
M Cenk AkbostancıNeurology Department, Ankara University School of Medicine, Ankara, Turkey.
Nuray YazihanPhysiopathology Department, Ankara University School of Medine, Ankara, Turkey.

Funding

Ankara Universitesi TSA-2022-2432
6 · The paper itself

Abstract

purposeParkinson's Disease (PD), a neurodegenerative disorder, is associated with substantial morbidity. α-Klotho, an anti-aging protein known for its neuroprotective properties, has gained attention. This study aims to assess serum levels of α-Klotho in PD patients.

methodsThis study is a cross-sectional case-control study. PD was diagnosed according to UK Parkinson Disease Society Brain Bank criteria. Serum α-Klotho level was measured using a commercially available enzyme-linked immunosorbent assay.

resultsOf the 314 participants in the study, 157 were patients with PD and 157 were controls. Lower levels of α-Klotho were observed in PD (0.85 nmol/L) in comparison to the controls (1.47 nmol/L, p < 0.001). α-Klotho levels were also significantly lower among PD patients with dementia compared to PD patients without dementia. In logistic regression analysis, α-Klotho (OR: 0.04, p < 0.001) demonstrated a significant relationship between PD. A significant correlation was identified between α-Klotho levels and Mini-Mental State Examination scores in PD patients. The sensitivity and the specifity of α-Klotho were 90% and 65% for predicting PD.

conclusionsOur findings suggest that α-klotho could potentially serve as a biomarker. However additional studies are needed to confirm our findings.

Indexed as

GlucuronidaseParkinson DiseaseAgedBiomarkersCase-Control StudiesCross-Sectional StudiesDementiaFemaleHumansKlotho ProteinsMaleMiddle AgedBiomarkersGlucuronidaseKlotho ProteinsKL protein, humanDementiaOlder individualsParkinson’s diseaseα-Klotho protein

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.